Cooperative Agreement U24AG092191
Award Date
9/30/24
Completion Date
8/31/29
Dollars Obligated
$5.1M
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Institute on Aging
Federal Grant Program
93.310
Assistance Type
Cooperative Agreement
Place of Performance
Aurora, CO 80045, USA
Similar Awards
The Department of Health and Human Services, through the Trans-NIH Research Support program (CFDA 93.310), has awarded a $1,999,508 Cooperative Agreement to RTI International and Emory University to establish the INCLUDE Down Syndrome Clinical Cohort Coordinating Center (DS-4C). The DS-4C will serve as the central hub to coordinate and integrate all components of the INCLUDE Down Syndrome Cohort Development Program, including overseeing protocol development, facilitating data collection and...
This $2,598,199 Cooperative Agreement, awarded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), will support a multi-center, multi-disciplinary research project titled "Advancing the Lives & Health of Youth and Young Adults with Down Syndrome (ALLY-DS)." The project aims to establish a diverse cohort of individuals with Down syndrome for comprehensive longitudinal phenotyping, including multi-omics data...
The federal Cooperative Agreement award U01HD116463, titled "The Infant Down Syndrome Brain and Behavior Study", is funded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The $2,927,457 award will support a longitudinal study to collect multimodal neuroimaging, cognitive/behavioral data, and social communication measures in a cohort of 100 infants with Down syndrome and 50 typically developing controls. The study aims to...
The National Institutes of Health Office of the Director awarded a $4,706,274 Project Grant to the University of Colorado Denver under the Trans-NIH Research Support program (CFDA 93.310) on September 9, 2022. The grant will fund research to develop novel computational strategies for analyzing multi-omics data from individuals with Down syndrome to better understand the molecular connections between trisomy 21 and co-occurring conditions. Specifically, the University of Colorado Denver will work...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,357,335 to study neuronal dysfunction in Down syndrome (DS) and its link to Alzheimer's disease (AD). The key products and services delivered under this award include: Utilizing induced pluripotent stem cell (iPSC)-derived cortical organoids and assembloids to examine the cellular, transcriptomic, and motility-related...
This Cooperative Agreement award, funded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), will support a 5-year, longitudinal study entitled "Metabolic Health, Lifestyle, and Risk of Co-Occurring Health Conditions in Down Syndrome (MET-DS)". The study will enroll 200 participants aged 6-24 years with Down syndrome across 4 clinical sites to deeply characterize metabolic health, obesity, and lifestyle...
This U01HD116485 Cooperative Agreement award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,644,869 to establish the "DOWN SYNDROME EARLY CHILDHOOD OMICS, DEEP PHENOTYPING, AND EPIDEMIOLOGY IN TEXAS: DECODE IT COHORT" research project at Baylor College of Medicine. The project aims to recruit 1,000 children with Down syndrome into a population-based birth cohort to conduct deep phenotyping and...
The National Institutes of Health (NIH) awarded a $5,386,286 Cooperative Agreement under the Trans-NIH Research Support program (CFDA 93.310) to the University of Colorado-Denver to develop the Human Trisome Project - Latin America Network. This project aims to study the unique clinical and developmental profiles of Latinos with Down syndrome, including multi-omics investigations to identify biological signatures associated with differential features. The award will establish a research...
This Project Grant award of $3,317,325.00 from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) will support research to investigate the role of immune dysregulation and nerve growth factor (NGF) dysfunction in the development of Alzheimer's disease (AD) in individuals with Down syndrome (DS). The key objectives are to: 1) elucidate the relationships between immune deregulation, NGF dysmetabolism, and AD hallmarks in DS brain tissue and cell cultures; 2)...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $322,000.00 to Case Western Reserve University to perform the following: Analyze electroencephalographic (EEG) and plasma Alzheimer's disease (AD) biomarker data collected during a previous clinical trial studying the effects of the drug memantine on adolescents and young adults with Down syndrome. The analysis will examine the...